Objective: This is the first part of a bipartite review that summarizes the rising knowledge on the molecular mechanisms underlying Ž . the action of advanced glycation endproducts AGEs and their contribution to diabetic complications and vascular disease. While the first part presented here focusses on AGE formation, the second part will describe the AGE-proteinrreceptor interactions and their role in mediating AGE-dependent intracellular signalling. Results: Nonenzymatic glycation, in which reducing sugars are covalently attached to free amino groups and ultimately form AGEs, has been found to occur during normal aging and at accelerated rate in diabetes mellitus. Oxidation, accompanying glycation in vivo, further supports chemical modifications. AGE formation and protein crosslinking are irreversible processes that alter the structural and functional properties of proteins, lipid components and nucleic acids. AGE modifications do not only change the physicochemical properties of the afflicted molecules, but also induce cellular signalling, activation of transcription factors and subsequent gene expression in vitro and in vivo. Conclusions: AGEs elicit a wide range of cell-mediated responses that might contribute to the pathogenesis of diabetic complications, vascular and renal disease and Alzheimer's disease. Substances that inhibit AGE formation, reduce oxidative stress or destroy already formed crosslinks may limit the progression of disease and may offer new tools for therapeutic interventions in the therapy of AGEs mediated disease. q 1998 Elsevier Science B.V.
Introduction

Ž
.w x Advanced Glycation Endproducts AGEs 1,2 accumuw x late during aging 3 and at accelerated rate during the w x course of diabetes 1,2,4 . They are believed to induce changes in endothelial cell properties relevant in the pathogenesis of vascular disease. Thus, AGEs are not only markers, but also mediators of chronic vascular complications.
Chemistry of 'advanced glycation endproducts' formation
Reactive derivatives of nonenzymatic glucose-protein condensation reactions, as well as lipids and nucleic acids ) Ž . Ž . Corresponding author. Tel.: q49-6221 568604; Fax: q49-6221 564101.
exposed to reducing sugars, form a heterogeneous group of irreversible adducts called 'Advanced Glycation Endprod-Ž . ucts' AGEs . AGEs were originally characterized by their yellow-brown fluorescent color and their ability to form w x crosslinks to and between amino groups 5 . The term 'AGEs' is now used for a broad range of advanced prodw x ucts of the Maillard reaction 6-8 including compounds as Ž . e Ž . Ž . 3,4 N -carboxymethyl lysine CML and pyrraline, which do neither show color and fluorescence, nor occur w x as crosslinks in proteins 9 . The formation of AGEs in vitro and in vivo is dependent on the turnover rate of the chemically modified target, time and sugar concentration.
Ž . In the classical pathway of AGE formation Fig. 1 , a Ž nonenzymatic reaction also called 'Maillard' reaction w x. 6,7 between glucose or other reducing sugars and Nterminal amino acid residues andror e-amino groups of proteins forms initially a Schiff base adduct. RearrangeTime for primary review 40 days. ment of this aldimine leads to the formation of reversible Amadori adducts such as fructose-lysine. Dehydration, successive b-eliminations and condensation reactions finally result in the production of irreversible 'crosslinks' w x that persist for the lifetime of the modified substrate 10 . A similar reaction takes place when glycerolaldehyde interacts with proteins and thereby mediates latent cross-linw x king potential to a-hydroxyaldehydes 11 . From all natural occurring sugars, glucose has the slowest glycation rate, while intracellular sugars as fructose, threose, glucose-6-phosphate and glycerolaldehyde-3-phosphate form w x AGEs at much faster rate 12-14 .
Oxidation, accompanying glycation in vivo, supports the formation of more permanent, irreversible chemical Ž . e modifications, such as the glycoxidation products 3,4 N -Ž . Ž . w x carboxymethyl lysine CML 15,16 and pentosidine w x 16,17 . CML forms from the Amadori product of glucose or threose through metal-catalyzed oxidative fragmentation w x w x 15,18 and through autoxidation of glucose 19,20 or w x ascorbate 21 . In the latter case, autoxidation converts ascorbate to dehydroascorbate, which is rapidly degraded to L-threose. Condensation reactions between two molecules of threose and the e-amino group of lysine lead Ž . w x to the formation of formyl-threosyl-pyrrole FTP 21 Ž . Fig. 2 . Oxidative cleavage of the Amadori product threulosyl-lysine generates CML. CML is also formed independent of the presence of fructose-lysine during w x metal-catalyzed oxidation of LDL 22 and peroxidation of w x polyunsaturated fatty acids 22 . In addition, CML can be formed from the precursors glyoxal and glycolaldehyde largely independent from glucose autoxidation by an intraw x molecular Cannizzaro reaction 19 .
Intermediates contributing to chemical modifications during AGE formation are dicarbonyl intermediates as 1-, w x 3-, and 4-deoxyaldosuloses 23,24 . The potent crosslinking intermediate desoxyglucoson, which rapidly inw x creases AGE-modifications in proteins 25 , is formed w x most probably only under nonoxidative conditions 26 . In addition, the dicarbonyl intermediates arabinose and glyoxal are generated through metal-catalyzed autoxidation of w x glucose 26 . From those, glyoxal has been demonstrated to be most important in AGE formation, since it easily 2 . Proposed mechanism for the formation of ascorbate-specific advanced glycation end products: Autoxidation converts ascorbate to dehydroascorbate, which is rapidly degraded to threose. Condensation of two threose molecules with the e-amino group of lysine residue results in Ž . w x the formation of formyl-threosyl-pyrrole FTP 21 . Ž forms crosslinks with arginine and lysine resulting in the . w x formation of pentosidine and CML 26 . Beside its formation from triosephosphates, the reactive a-oxoaldehyde methylglyoxal can also be formed enzymatically in the acetolracetone metabolism by elimination of phosphate from dihydroxyacetone phosphate and subsequent oxidaw x tion 27 . Reduction of methylglyoxal by aldose reductase Ž . results in the formation of acetol 95% and D-lactatalde-Ž . hyde 5% . Further reduction of acetol results in the generation of L-1,2-propandiol, that has been demonstrated to accumulate in badly controlled diabetes mellitus. Since methylglyoxal and acetol are potent crosslinking agents, the aldose reductaserpolyol pathway also promotes AGE w x formation 28,29 .
Metal-catalyzed autoxidation of glucose in the presence or absence of protein is paralleled by the generation of Ž . w x reactive oxygen species ROS as superoxide radicals 30 w x that can undergo dismutation to hydrogen peroxides 31 .
Ž . Incubation of proteins, low density lipoproteins LDL or phosphatidylcholine liposomes with glucose under oxidiz-Ž ing conditions in the presence of transition metals e.g.
. copper also results in increased protein fragmentation, carbohydrate incorporation and generation of thiobarbituric w x acid reactive species and hydrogen peroxides 32,33 . In w x the transition metal mediated 'Fenton reaction' 34 hydrogen peroxides can produce highly reactive hydroxyl radi-Ž . w x cals Fig. 3 31,32 . Thus, not only glycation but also oxidative damage of macromolecules as peroxidation of w x LDL 32 accounts for the alterations observed during w x 'AGE'ing 16,35 . A recent report therefore supposes that formation of glycoxidation products in vivo does not only depend on the relative glucose concentrations, but also on w x the local oxidative environment 33 .
Oxidative modifications and chemical modification resulting from advanced glycation have been demonstrated w x to affect the clearance of LDL 36 . Increased levels of w x AGEs on LDL from diabetic individuals 36 indicate that LDL-AGE formation accompanies LDL oxidation and therefore might be a primary mechanism for the pathogenic w x modification of LDL 37 . This view is emphasized by the observation that lysosomal degradation of AGE-LDLs in macrophages is much slower than degradation of acetyw x lated or oxidized LDL 38,39 . Recently it has been suggested that glucose directly acts with phosphatidylethanolamine and phosphatidylserine to form AGEs Ž . w x on phospholipids Fig. 4 37 . Intramolecular oxidationreduction reactions might then oxidize fatty acid residues independently of the presence of transitions metals or free-radical generating systems. AGEs formed on matrix components of the vessel wall or the kidney can further cross-link and trap plasma prow x teins, lipoproteins and immunoglobulins 2,37,40 . Since small soluble AGE peptides, released into the circulation after macrophage dependent degradation of AGE proteins, readily react and covalently bind to proteins as collagen w x and plasma LDL in vitro 41 , it is supposed that reactive intermediates released from naturally degraded tissue AGEs can bind again and thereby form 'second' generation AGEs w x 37 . If the clearance of circulating low-molecular weight AGE-modified substances is delayed, the degraded AGE macromolecules therefore include reactive substances, w x which further permit the formation of new crosslinks 37 Ž . Fig. 5 .
The cellular actions of AGEs
AGE formation was originally thought to specifically tag senescent proteins, thereby providing a specific signal for recognition, degradation and removal of senescent w x macromolecules 2,42 . Low molecular weight AGE-rich Ž . peptides LMW-AGE were identified as degradation products and are presumably released into the circulation to be w x cleared by the kidneys 43,44 . Recent studies, however, demonstrate that interactions of AGE modified proteins with different AGE-receptor complexes not only serve to degrade AGE-proteins, but also activate signal transduc-Ž . tion pathways Table 1 , that induce the synthesis and release of cytokines and growth factors that might initiate w x tissue repair and protein turnover 45 , but also contribute to the development of vascular disease and diabetic comw x plications 1,2 . A large number of studies recently confirmed the close correlation between AGE formation and physiologic changes observed in vascular disease, diabetes, atherosclerosis and aging.
Since intracellular sugars are much more reactive than w x glucose 46 , intracellular AGE formation occurs extremely fast. In vitro experiments demonstrated that 1 week incubation of endothelial cells in the presence of high glucose results in an 13.8-fold increase in the intracellular AGEw x contet 47 . In parallel, the mitogenic activity of high glucose cultivated endothelial cells markedly decreased. The observed loss in mitogenic activity was due to posttranslational modifications of basic fibroblast growth fac-Ž . tor bFGF by AGEs representing the major AGE-modw x ified protein in endothelial cells 47 . AGE formation on the extracellular matrix results in decreased elasticity, increased thickness, rigidity, breaking time and narrowing the vessel lumen. AGEs formed on vascular matrix proteins mediate defects in the vasodila-Ž . w x tory response by inactivating nitric oxide NO 67 . In parallel, AGEs induce the expression of the potent vasoconstrictor endothelin-1 and change endothelial function w x towards vasoconstriction 68 . w x Binding of AGEs to their cellular binding sites 74 results in depletion of cellular antioxidant defense mecha-Ž . w x nisms e.g. glutathione, vitamin C 70 and the generation of oxygen free radicals. As consequence, increased cellular oxidative stress lead to the activation of the free radical sensitive transcription factor NF-kB in vitro and in vivo Ž . Fig. 6 and thus promotes the expression of NF-kB regulated genes such as the procoagulant Tissue Factor w x w x 55,61 or the adhesion molecule VCAM-1 63,64 , that has been associated with early stages of atherosclerosis. Induction of Tissue Factor expression and the parallel w x AGE-dependent reduction in thrombomodulin activity 55 changes the dynamic endothelial balance from an anticoagulant to an procoagulant state resulting in focal thrombosis and vasoconstriction. AGE-dependent induction of VCAM-1 can prime the vasculature for enhanced interacw x tion with circulating monocytes 63 . Thus, excessive deposition of AGEs might attract monocytes to bind to the vessel surface, to transmigrate the vessel wall and to release mediators that potentially contribute to the develop-Ž . ment of vascular lesions Table 2 .
Effects of 'advanced glycation endproducts' in vivo
AGEs formation proceeds slowly under normal ambient sugar concentrations, but is enhanced in the presence of hyperglycemia andror under conditions, where the protein and lipid turnover is prolonged. First evidence for posttranslational glucose modifications of proteins came from Ž . structural studies on human hemoglobin Hb , in which the variant HbA was found to carry an glucose-Amadori The structure of the different crosslinked AGEs, that are generated in vivo, has not yet been completely determined. Because of their heterogeneity and the complexity of the chemical reactions involved, only some AGE structures have been structurally characterized in vivo. CML and pentosidine have been found to accumulate in tissue collagen of the human skin with age and at accelerated rate in w x diabetes mellitus 78,79 . CML has also been described in w x w x human lens 80 and urine 81 . In addition, pyrralinespecific antibodies detected AGEs in sclerosed glomeruli of kidneys from old nondiabetic animals as well as in w x diabetic kidneys 82 . Increased pyrraline contents of plasma proteins have also been described in diabetes melliw x tus 83 . However, there are still doubts whether pyrraline w x forms under physiological conditions 27,82-84 . Dicarbonyl intermediates have been found to be elevated in w x plasma and urine of patients with diabetes mellitus 85,86 and a 3-to 6-fold increase in methylglyoxal has been reported in serum of patients with NIDDM and IDDM, w x respectively 87 .
Beside these structurally characterized AGEs, a large number of studies describes the detection of uncharacterized AGEs in serum and tissue proteins, identified by w x ELISA and RRA techniques 88,89 or immunohistochemistry using antibodies developed to proteins browned by w x glucose 90-92 . The AGEs recognized by these antibodies Ž . Ž . were defined by i yellow-brown color, ii fluorescence, Ž .
Ž . iii crosslinking andror iv their interaction with AGEspecific receptors, but were not structurally defined. Although CML might represent the majority of the structures w x recognized by these antibodies 9 , it cannot be excluded that other brown-fluorescent and crosslinking AGE strucw x tures are also detected 9 . Using these antibodies, increased serum levels of AGEs in very young prepubertal and pubertal IDDM diabetic patients were detected shortly w x after manifestation of diabetes 93 . This indicates that the pathological process leading to diabetic late complications starts at very early timepoints. AGEs were further detected in coronary atheroma and in cardiac and renal tissues in w x patients with diabetes mellitus 94-96 . In diabetic kidneys, AGEs were preferentially localized in the renal w x w x w x cortex 97 , mesangial areas 98 , vascular lesions 95 and w x glomerular basement membranes 95,97-99 . The accumulation of AGEs in the glomerular extracellular matrix is supposed to contribute to renal diabetic nephropathy w x 45,100 . Consistently, serum AGE levels correlate with the progressive loss of kidney function and are up to 8-fold elevated in individuals with end-stage renal disease requirw x ing dialysis 44 . Diabetic patients with uremia have also w x an increased risk for cardiovascular complications 2 . Inefficient clearance of degraded low molecular weight Ž . AGE-rich peptides LMW-AGEs and recirculation of these 'toxic' middle molecules might therefore not only account w x for uremia 94-96,101 , but also perpetuate extrarenal vascular damage in these patients. AGEs were also dew x tected in diabetic red blood cells 77 and in liver histones w x of diabetic rats 102 . The latter one might account for w x increased theratogenity associated with diabetes 102 . The recently identified guanine advanced glycation endproduct 2 Ž . N -1-carboxyethyl guanine is also supposed to contribute w x to mutations and DNA transpositions 103 .
Further confirmatory evidence for AGEs being central mediators of late diabetic complications was provided by animal models, in which an 8 weeks lasting administration of AGEs to euglycemic rats resulted in glomerular and arteriolar basement thickening, mesangial expansion and glomerulosclerosis with proteinuria and albuminuria and w x vascular dysfunction 51,58,104 . Significant AGE deposits were also detected in the retinal vasculature of AGE-inw x fused rats as well as in rats with long-term diabetes 105 . Short-term administration of in vitro prepared AGE-albumin produced vascular defects as vascular permeability and leakage, unresponsiveness to vasodilatory agents, w x subendothelial mononuclear recruitment 55,89,93 , activation of the transcription factor NF-kB and subsequent w x VCAM-1 gene expression 63,64,106 and thus underlined the concept of AGEs as modulators of the vascular tone in diabetes and vascular disease.
Besides diabetes mellitus, increased AGE levels were described in diseases associated with amyloid formation as haemodialysis-associated b2-microglobulin containing w x w x amyloidosis 107 and Alzheimer's disease 108-114 . Furthermore, AGEs were detected in healthy persons with a w x long history of smoking 115 , in patients with vascular w x disorders in the absence of diabetes 115 and in aortic atherosclerotic lesions in patients lacking a history of w x diabetes 92 . In the latter, extracellular deposition and intracellular accumulation of AGEs in the intimal lesions Consistently, long term infusion of physiological amounts of AGE-modified serum albumin into nondiabetic rabbits resulted in AGE accumulation in aortic tissues associated with intimal changes and focal expression of the w x adhesion molecules VCAM-1 and ICAM-1 64 . Thus, it is hypothesized that continuous AGE deposition might potentially promote the development of atherosclerotic lesions w x 37 . This view is emphasized by the finding that AGEs were detected in atherosclerotic lesions of euglycemic LDL-receptor deficient rabbits in areas rich in lipids and w x lipoproteins 117 and in lung collagen of old euglycemic w x rats 128 .
Exogenous 'advanced glycation endproducts'
Recent studies demonstrate that AGEs are found in cooked food and remain active in the circulation after oral uptake. The renal clearance of food AGEs is markedly impaired in individuals with diabetes compared to non-diabetics and therefore might represent an additional risk for w x w x Ž . AGE toxicity 129 130 Fig. 7 . Another source of orally administered AGEs seems to be smoking, since significantly increased serum AGE levels have been observed in w x diabetic smokers compared to diabetic non-smokers 131 . Therefore it seems reasonable that ''breaking the curse of w x the AGEs'' 132 is not exclusively restricted to therapeutic interventions with old and new drugs, but can at least in part be supported by an antioxidant diet and a healthy life style.
Pharmacological inhibition of 'advanced glycation endproducts' and possible therapeutic interventions
Aminoguanidine-HCl and other inhibitors of adÕanced glycation
Aminoguanidine is a small nucleophilic hydrazine compound. Its terminal amino group reacts specifically with non-protein-bound glucose-derived intermediates of early glycation products such as 3-deoxyglucosone. This results in the formation of 3-amino-5-and 3-amino-6-substituted w x Ž . triazines 133,134 Fig. 8 , which prevent the further rearrangement of intermediates to protein-protein and protein-lipid crosslinks. Since the first description of w x aminoguanidine action 135 , a large number of studies have confirmed that aminoguanidine prevents AGE formaw x tion and AGE-related complications in vivo 2,37,45,136 Ž . Table 3 .
Animal models demonstrated an aminoguanidine-mediated decrease of AGE accumulation in the large arteries w x w x 139 , the glomerular basement membrane 141,142 and in w x the retina of diabetic animals 124 and improved abnorw x malities of the diabetic peripheral nerve 147 . Furthermore, a recent study demonstrated that continuous application of aminoguanidine to non-diabetic rats reduced the age-associated increase in serum and tissue AGEs and protected from the aging-dependent progressive decline in w x cardiovascular and renal function 149 . Although aminoguanidine is regarded as a virtually nontoxic sub-Ž . w x stance LD s 1800 mgrkg in rodents 141 , recent stud- 50 ies demonstrated that high doses of aminoguanidine generate hydrogen peroxides and inhibit catalase, whereas inhibition of catalase is dependent upon the endogenous H O 2 2 w x production 150 . Chronic administration of aminoguanidine therefore might promote side effects relating to inhibition of catalase as acatalasaemia or suppressed iodine w x uptake by the thyroid 150 . First clinical studies evaluating its efficacy in diabetic patients have been started in the United States and in Canada. A small study, in which 30 diabetic patients were randomized and treated with aminoguanidine or placebo for 28 days, showed that aminoguanidine treatment significantly decreased hemoglobin-AGE, while HbA -values 1c w x were not affected 77 . Another significant effect of aminoguanidine has been the lowering of triglycerides, w x LDL-cholesterol and VLDL-cholesterol 41 . The latter observation is consistent with the hypothesis that AGE modifications significantly delay LDL-clearance by w x macrophages 36 . However, at present it remains unclear, whether the therapeutic effects of aminoguanidine are only due to inhibition of AGE formation.
Recently, the hypoglycemic drug OPB-9195 has been described to act as potent inhibitor of advanced glycation w x 151 . The thiazolidine derivate reduced AGE formation and AGE-derived crosslinks in vitro and in vivo at signifiw x cantly lower doses than those of aminoguanidine 151 . OPB-9195 prevented the progression of diabetic glomerular sclerosis in a diabetic rat model even under conditions w x of persistent hyperglycemia 151 . Up to date, however, clinical studies are missing to evaluate the therapeutic benefits of OPB-9195 in ameliorating diabetic nephropa- thy. Beside aminoguanidine and OPB-9195, the anti-dew x mentia drug tenilsetam 152,153 and the natural occurring w x dipeptide carnosine 154,155 have been described to successfully reduce glycation and crosslinking.
AGE-crosslink 'breakers'
While aminoguanidine prevents ongoing AGE formation, it will probably be not effective in patients with a long history of disease that already resulted in extensive tissue-AGE accumulations. The need to remove irreversibly bound AGEs from connective tissues and matrix compounds led recently to the design of AGE-cleaving agents as the prototypic AGE crosslink 'breaker' N-Ž . w x Ž . phenacylthiazoliumbromide PTB 156 Fig. 9 . Based on the hypothesis that the majority of AGE crosslinks formed from glucose involve an a-diketone moiety, PTB specifically attacks the carbon-carbon bond of a-diketones and thereby breaks the carbon-carbon bond between two carw x Ž . bonyls of an AGE crosslink 156 Fig. 9 . First experiments demonstrated the ability of PTB to reduce AGE w x crosslinks in vitro and in vivo 156 . Although further studies are needed to proof directly the evidence for the formation of a-diketones in vivo, this new class of 'crosslink breakers' provides a rational basis for a broad clinical w x application 156 .
Antioxidants
Under physiological conditions, free radicals are rapidly eliminated by antioxidative defense mechanisms such as the glutathione redox system, the vitamin Crvitamin E Table 3 Effects of aminoguanidine cycle and the a-lipoic acidrdihydrolipoic acid redox pair w x 157 . In diabetic patients antioxidant capacity is decreased, resulting in an increased susceptibility to oxidaw x tive stress 158-162 . Reactive oxygen radicals play a central role in the generation of intracellular AGEs by w x sugar adduct autoxidation 32,78,163,164 . Antioxidants as a-tocopherol, a-lipoic acid, deferioxamine or dimethylsulfoxide have been demonstrated to inhibit hyperglycemia-induced reactive oxygen species and AGE formation in vitro. Aspirin administration seems to inhibit protein glucose modifications in diabetic animals and to demonstrate protective effects in age-related cataractogenew x sis in humans 165 .
In addition, AGEs bound to their endothelial surface receptor RAGE have been demonstrated to induce the w x oxidative-stress sensitive transcription factor NF-kB 69 .
Reactive oxygen species dependent NF-kB activation can Ž be inhibited in the presence of antioxidants a-lipoic acid, Ž . vitamin E, N-acetylcysteine Nac or pyrrolidinedithio-Ž . w x carabamate pDTC in vitro and in vivo 157 . Thus, antioxidants do not only reduce the formation of AGEs w x 166 , but also suppress AGE-mediated intracellular effects w x 70 .
The dual concept of antioxidant protection was underlined by experiments in which the peroxidation-suppressing w x protooncogene bcl-2 was overexpressed 167 . Overexpression of bcl-2 protected cells from lipid peroxidation and w x AGE formation 167 . This effect might be due to a yet unknown peroxidase or reductase activity of bcl-2. However, it has been shown that the bcl-2 related protein bcl-X did not only protect cells from oxidative stress, but L also from NF-kB activity by binding to its carboxy-terminal end. Thereby bcl-X modifies NF-kB transactivating L capacity even after translocation of NF-kB into the nucleus. The dual effects of antioxidants and the oxidationsuppressing protooncogene bcl-2 on AGE mediated cellular activation might therefore offer additional strategies for the potential prevention of AGE mediated disease.
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